Vascular Biogenics Ltd (VBLT.OQ)
24 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|77||2007||Chairman of the Board, Independent Director|
|60||2001||Chief Executive Officer, Director|
|61||2016||Chief Financial Officer & Company Secretary|
|50||2014||Vice President - Research & Operations|
|43||2014||Vice President - Business Operations|
- BRIEF-Vbl Therapeutics Announces Q1 Loss Per Share $0.24
- BRIEF-VBL Therapeutics Awarded $2.5 Million Non Dilutive Grant By The Israel Innovation Authority
- BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma
- BRIEF-VBL Therapeutics Receives Milestone Payment From Nanocarrier Under Licensing Agreement For VB-111 In Japan
- BRIEF-Vascular Biogenics Says Top-Line Data From Globe Phase 3 Pivotal Trial Of VB-111 Expected In Q1 Of 2018